Abstract Details

Title Real-World Local Field Potential Recordings in Patients with Parkinson’s Disease: Peak Detection and Influence of Patient Related Factors

Topic Movement Disorders

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-011

Objective To determine the association of real-world local field potential (LFP) recordings in patients with Parkinson’s disease (PD) with mobility quality of life (m-QoL), patient demographics, interhemispheric recordings, and stimulation parameters.

Background LFPs are associated with various symptoms in PD and are considered a biomarker of interest for deep brain stimulation (DBS). However, real-world LFP data is limited.

Design/Methods Twenty-seven patients (age: 63.7±9.4-years, Sex: 18-male, Disease Duration: 12.9±7.3-years) with PD and bilateral subthalamic nucleus DBS (STN-DBS) were included. Recordings occurred during routine clinic visits, OFF stimulation. Raw LFP data was processed to identify spectral peaks and frequency band power in the alpha, beta, and gamma ranges. M-QoL was assessed using the EuroQol-5 Dimensions (EQ-5D) question 1. Due to non-normally distributed data, non-parametric tests were used for all analyses with significance set at p<0.05.

Results Peaks were detected in 42(77.8%) of 54 STNs with 18(66.7%) patients demonstrating bilateral peaks and 6(22%) demonstrating unilateral peaks. No significant differences were found in LFP characteristics between hemispheres (p>0.05). Interhemispheric peak frequency (rho=0.46, p=0.06) and amplitude (rho=0.34, p=0.162) demonstrated non-significant interhemispheric correlations. Interhemispheric band power demonstrated a significant correlation in the low-beta (rho=0.43, p=0.027) and high-beta (rho=0.42, p=0.031) ranges. Those with worse m-QoL demonstrated increased low- (Z=-2.47, p=0.012, eta squared=0.23) and high-beta (Z=-2.26, p=0.023, eta squared=0.20) band power. No sex differences were noted across peak characteristics and beta band power averages (p>0.05). Peak characteristics and beta band power primarily demonstrated non-significant correlations with age, disease duration, and stimulation amplitude (p>0.05).

Conclusions

LFP peaks were readily detected in real-world, clinical settings. Elevated STN low- and high-beta band power of patients with PD may be linked to worse m-QoL. This information, along with other significant findings related to STN LFPs, may guide further treatment of patients with PD and improve our understanding of PD pathophysiology.

Authors/Disclosures
Nathan Morelli, PhD, PT (High Point University) PRESENTER	Dr. Morelli has received personal compensation for serving as an employee of Medtronic.
Alexa Singer	Alexa Singer has received personal compensation for serving as an employee of Medtronic.
	No disclosure on file
Hideo Mure, MD, PhD (Feinstein Inst. for Medical Research)	No disclosure on file
Kenneth P. Martinez, MD (Neurology & Pain Specialty Center)	The institution of Dr. Martinez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. The institution of Dr. Martinez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie/Allergan. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. The institution of Dr. Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie/Allergan. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Merz. The institution of Dr. Martinez has received research support from Medtronic. The institution of Dr. Martinez has received research support from Abbvie/Allergan.
Genko Oyama, MD, PhD, FAAN (Saitama Medical University)	Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medtronic. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Otsuka Pharmaceutical Co. Ltd.. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sumitomo Dainippon Pharma Co. Ltd.. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai Co., Ltd.. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda Pharmaceutical Company LTD.. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Hakko Kirin Co. Ltd.. Dr. Oyama has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie, Inc. The institution of Dr. Oyama has received research support from AbbVie, Inc. The institution of Dr. Oyama has received research support from GLORY LTD. The institution of Dr. Oyama has received research support from Kirin Company LTD. The institution of Dr. Oyama has received research support from Mitsubishi UFJ Lease & Finance Company LTD. The institution of Dr. Oyama has received research support from Sunwels Co., Ltd. The institution of Dr. Oyama has received research support from Ohara Pharmaceutical Co.,Ltd.. The institution of Dr. Oyama has received research support from PARKINSON Laboratories Co., Ltd..
	No disclosure on file
	No disclosure on file
Mya C. Schiess, MD, FAAN (Univ of Texas-Houston Med School)	Dr. Schiess has nothing to disclose.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��